Trial Profile
Phase II Clinical Trial to Analyze the Safety and Efficacy of Vedolizumab Combined With Antiretroviral Therapy to Achieve Permanent Virological Remission in HIV-infected Subjects Without Previous Antiretroviral Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary) ; Dolutegravir; Emtricitabine/tenofovir alafenamide; Hydrocortisone
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 21 Nov 2021 Status changed from recruiting to completed.
- 22 Jun 2018 Planned End Date changed from 28 May 2020 to 1 May 2020.